OTV (Olive Tree Ventures)

OTV (formerly Olive Tree Ventures) is a global specialist venture capital firm exclusively dedicated to digital health, founded in 2015 and headquartered in Tel Aviv, Israel with additional offices in New York, Montreal, and Shanghai. Co-founded by General Partners Mayer Gniwisch, Amir Lahat, and Alejandro Weinstein, who together bring backgrounds spanning healthcare, technology, private equity, and financial services, the firm is widely recognized as Israel's only major VC whose primary investment focus is digital health. Partner Manor Zemer complements the founding team. OTV closed a dedicated $170 million digital-health growth fund in December 2020, anchoring its international expansion including the opening of its Asia office in Shanghai. The firm leads rounds across 45 investments and covers the full arc of digital health: telemedicine and virtual care, genomics, AI-powered clinical decision and diagnostics platforms, digital biomarkers, precision medicine, and next-generation medical-device software. Notable portfolio companies include TytoCare (remote examination kit, whose $50 million round OTV led alongside Insight Partners and Qualcomm Ventures) and Scopio Labs ($16 million Series B that OTV led in December 2023, advancing digital microscopy and AI pathology). Realized exits include Lemonaid Health (acquired by 23andMe) and Emedgene (acquired by Illumina). OTV focuses particularly on companies reaching commercial maturity, partnering with founders to navigate regulatory, reimbursement, and enterprise sales challenges across five continents. Its combination of Israeli innovation sourcing, US capital-market relationships, and Asian commercial networks makes it a genuinely global platform for digital health at growth stage.